Answers are grounded in this paper and cite their sources.
Evaluates renal perfusion using MRI against gold-standard clearance in diabetes, highlighting method implications.
Introduction and Objective: Multiparametric kidney MRI is increasingly employed as an endpoint in mechanistic diabetic kidney disease (DKD) trials. While traditional clearance-based renal plasma flow (RPF) reflects global hemodynamics, it often fails to detect microvascular dysfunction in early DKD. Arterial spin labeling (ASL) allows for non-invasive, spatial assessment of perfusion. We evaluated the concordance of ASL-derived flow against gold-standard clearance methods. Methods: We assessed cross-sectional associations between pseudocontinuous-ASL (pcASL) perfusion, acquired on a 3T Siemens Skyra scanner, and gold-standard plasma p-aminohippurate (PAH) clearance. An MRI-derived “Total Flow (TF) Proxy” (mL/min) was calculated as (Cortical Perfusion Rate × Total Kidney Volume) / 100. This proxy was compared against PAH-derived effective RPF (eRPF). The study included 152 participants classified as: Type 1 Diabetes (T1D; n=22, mean age 24±3, mean BMI 26.0 ± 2.8 kg/m², mean mGFR 149.9 ± 23.3 mL/min, mean UACR 8.6 ± 10.3 mg/g), Type 2 Diabetes (T2D; n=41, mean age 19±7, mean BMI 33.2 ± 7.5 kg/m², mean mGFR 182.9 ± 58.9 mL/min, mean UACR 27.2 ± 29.7 mg/g), and Healthy Controls (HC; n=89, mean age 16±6, mean BMI 25.8 ± 7.3 kg/m², mean mGFR 134.2 ± 25.5 mL/min, mean UACR 65.6 ± 302.0 mg/g). Results: In the combined population, the pcASL TF Proxy demonstrated moderate correlation with eRPF (r=0.36, p<0.0001). Subgroup analysis revealed significant correlations in the HC group (r=0.41, p<0.0001) and T2D participants (r=0.312, p<0.05). Notably, no significant correlation was observed in T1D participants (r =0.24, p>0.05). No significant differences were observed based on sex. Conclusion: ASL-derived perfusion imaging shows moderate concordance with gold-standard PAH clearance in T2D and healthy controls. The lack of strong concordance suggests that ASL captures distinct hemodynamic information (regional perfusion) separate from global clearance. These findings support the use of ASL MRI as complementary mechanistic endpoint trials. Disclosure S. Ramesh: None. J.D. Weissenkampen: None. Y. Choi: None. P. Narongkiatikhun: None. M. D'Antonio: None. H. Hampson: None. N. Nguyen: None. M.L. Granda: None. K. Tommerdahl: Advisory Panel; Current; Sanofi. D. van Raalte: Consultant; Current; AstraZeneca. Research Support; Current; AstraZeneca. Consultant; Current; Boehringer Ingelheim International GmbH. Research Support; Current; Boehringer Ingelheim International GmbH. Consultant; Current; Eli Lilly and Company. Research Support; Current; Eli Lilly and Company. Consultant; Current; Merck & Co., Inc. Research Support; Current; Merck & Co., Inc. Consultant; Current; Novo Nordisk. Research Support; Current; Novo Nordisk. L. Pyle: None. P. Bjornstad: Consultant; Current; Bayer AG, Boehringer Ingelheim International GmbH, Lilly, Novo Nordisk. Funding National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK129211); National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK116720); National Heart, Lung, and Blood Institute (K24 HL145076-02); National Center for Advancing Translational Sciences, Colorado Clinical and Translational Sciences Institute (TL1 TR002533); Breakthrough T1D (2-SRA-2019-845-S-B); Breakthrough T1D (2-SRA-2018-627-MB)
No takes yet. Share an insight, caveat, or question.
Ramesh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: